Biotech Values

[jq1234]

Not necessarily. MPNs are complex. As far as I can tell based on the limited data, no one drug can take care of ALL. In that regard, Imetelstat might not be a competitor for JAK inhibitors, rather complement each other in some way, like Revlimid and Velcade in MM. That's my initial take, have to see more data from Imetelstat, JAK1, JAK2.